Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Frankfurt - Delayed Quote EUR

Otsuka Holdings Co., Ltd. (OS1.F)

46.80

0.00

(0.00%)

At close: April 4 at 8:05:45 AM GMT+2

EC approves Otsuka and Lundbeck’s Rxulti for schizophrenia

The decision was supported by a randomised, six-week, placebo-controlled trial involving 316 adolescent subjects.

Pharmaceutical Technology 23 days ago

OTSKY
Otsuka’s sibeprenlimab shows promise in Phase III IgA nephropathy trial

Interim data from Otsuka's trial of sibeprenlimab indicates a significant reduction in proteinuria in IgA nephropathy patients.

Clinical Trials Arena 5 months ago

OTSKY
Otsuka’s startup bet pays off with kidney disease drug results

A medicine the pharma acquired in a 2018 buyout of Visterra succeeded in a Phase 3 trial in IgA nephropathy, a crowded corner of drug research.

BioPharma Dive 5 months ago

OTSKY
Otsuka snaps up Jnana with its phenylketonuria drug for $800m

The acquisition is expected to conclude in Q3 this year and will see Otsuka adding Jnana’s Phase I/II phenylketonuria therapy to its rare disease portfolio.

Clinical Trials Arena 7 months ago

OTSKY

SYBX
Otsuka buys startup Jnana, adding to uptick in private biotech M&A

The $800 million deal hands Otsuka a drug that’s shown promise in early testing in phenylketonuria, and is the fourth buyout of a privately held biotech in the last two weeks alone.

BioPharma Dive 8 months ago

OTSKY
Ionis (IONS) Expands Licensing Deal With Otsuka for HAE Drug

Ionis (IONS) out-licenses the rights for its HAE drug to Otsuka in the Asia-Pacific region. The companies signed a similar deal last year granting Otsuka rights to market the drug in Europe.

Zacks 9 months ago

IONS

OTSKY

NVS
Otsuka and Lundbeck report data from three PTSD treatment trials

In the trials, the brexpiprazole plus sertraline regimen was associated with a statistically significant reduction in PTSD symptoms.

Clinical Trials Arena 10 months ago

OTSKY

Performance Overview

Return	OS1.F	Nikkei 225 (^N225)
YTD	-10.00%	-15.33%
1-Year	+1,461.38%	-15.07%
3-Year	+15,953.26%	+21.79%